Wiley, a global leader in research and learning, has appointed Karen N. Madden, Ph.D., to its Board of Directors. Madden, who serves as Senior Vice President and Chief Technology Officer at MilliporeSigma, brings extensive experience in research, technology strategy, and innovation leadership.
At MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, Madden shapes the company’s Technology Roadmap and long-term R&D strategy, guiding scientific and technological advancements. She is a member of the Life Science Executive Team, driving initiatives that support both high-impact innovation and near-term growth.
Madden has worked extensively with universities, startups, and industry organizations, fostering collaborations that advance life sciences research. She previously served as Senior Vice President and Chief Innovation Officer at PerkinElmer, leading innovation strategies across multiple industries.
She holds a Ph.D. in chemistry from Rutgers University’s Center for Advanced Biotechnology and Medicine, with a focus on molecular biology, biochemistry, and biophysics. Madden also earned a Master of Science in chemistry from the University of Pennsylvania and a Bachelor of Arts in chemistry from Boston University. She serves on the Board of the Analytical, Life Science, and Diagnostics Association, the New England Council, and the Greater Boston Chamber of Commerce.
Click here to read the original press release.
